ClinicalTrials.gg
CompletedNCT00325234Updated May 20, 2011Results posted

Pemetrexed-Carboplatin and Gemcitabine-Vinorelbine in Advanced Breast Cancer

A Phase 2 interventional study of Pemetrexed and Carboplatin in Breast Cancer, sponsored by Eli Lilly and Company. Completed at 22 sites in 5 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-05-20.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
135
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing pemetrexed in Breast Neoplasms — none open to participants now, none under way, none of them phase 3. Pemetrexed · Breast Neoplasms.

Enrollment
2nd of 13
135 · median 50
Started
2006
the only one that year
Phase 2
10 of 14
none open now
Registered
10th of 14
by date
Lead sponsor
10 of 14
Eli Lilly and Company

Among the 14 studies testing pemetrexed in Breast Neoplasms, this one is the 2nd largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2006, is one of 10 in phase 2, and was the 10th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

None of the 14 studies testing pemetrexed in Breast Neoplasms is open now. The open studies under Breast Neoplasms, anywhere →

About pemetrexed

Pemetrexed: first FDA approval 2004 (ALIMTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies testing pemetrexed in Breast Neoplasms as a file.
02

Study summary

The primary purpose of this study is to help answer the following research questions:

  • whether the chemotherapy combination therapy Pemetrexed-Carboplatin or Gemcitabine-Vinorelbine can help participants with advanced breast cancer to make the tumor smaller or disappear and for how long
  • to learn more about the side effects in each chemotherapy combination treatment arm
  • to assess how participants with advanced breast cancer report health changes while receiving any of the chemotherapy combination arm
03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Females with histologic or cytologic diagnosis of advanced breast cancer. Lesions should not be amenable to surgery or radiation of curative intent.
  • Performance status of 0 to 2 on the (ECOG) performance status scale.
  • One prior chemotherapy containing anthracyclines as (neo) or palliative treatment.
  • One prior chemotherapy containing taxanes as (neo) adjuvant or palliative 1st-line treatment.
  • Prior radiation therapy is allowed to less than 25% of the bone marrow. Participants must have recovered from the toxic effects of the treatment prior to study enrollment (except for alopecia). Prior radiotherapy must be completed 30 days before study entry. Lesions that have been radiated cannot be included as sites of unless clear tumor progression has been documented in these lesions since the end of radiation therapy.
  • At least one uni-dimensionally measurable lesion meeting (RECIST) criteria. Positron emission tomography [PET] scans and ultrasounds may not be used.
  • Antitumoral hormonal treatment must be discontinued prior to enrollment.
  • Estimated of at least 3 months.
  • Participant compliance and geographic proximity that allow adequate follow-up.
  • Adequate organ function
  • Female participants of must test negative for pregnancy within 7 days of enrollment based on a urine and/or serum pregnancy test and agree to use a reliable method of during and for 6 months following the last dose of study drug.
  • Participants must sign an document.
  • Female participants must be at least 18 years of age.

Exclusion criteria

Exclusion Criteria:

  • Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.
  • Have previously completed or withdrawn from this study or any other study investigating Pemetrexed, Gemcitabine, Carboplatin or Vinorelbine
  • Have received more than one in Breast Cancer. Participants having received more than one combination of anthracycline plus taxane.
  • Are pregnant or breast-feeding.
  • Have serious concomitant systemic disorders (e.g., active infection) that, in the opinion of the investigator, would compromise the safety of the participant or compromise the participant's ability to complete the study.
  • Have a prior other than breast cancer, carcinoma in situ of the cervix, or nonmelanoma skin cancer, unless that prior malignancy was diagnosed and definitively treated at least 5 years previously with no subsequent evidence of recurrence.
  • Are unable to interrupt aspirin or other nonsteroidal anti-inflammatory agents for a 5-day period (8-day period for long-acting agents such as piroxicam), unless the is greater than or equal to 80 ml/min.
  • Have central nervous system (CNS) metastases.
  • Have (by physical exam) third-space fluid collections (for example, ascites or pleural effusions) that cannot be controlled by drainage or other procedures prior to study entry.
  • Are unable or unwilling to take folic acid, vitamin B12 supplementation, or dexamethasone.
  • Concurrent administration of any other antitumor therapy.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
135 participants (actual)

Study arms

  • Experimental
    Pemetrexed/Carboplatin

    Pemetrexed 600 mg/m\^2 was administered intravenously over approximately 10 minutes on Day 1. Carboplatin was given over approximately 30 minutes on Day 1 beginning after the end of the Pemetrexed infusion, consistent with a target of AUC (Area under the plasma drug concentration versus time curve) 5.0 mg\*min/mL. The cycle of treatment was 21 days.

    Drug: Pemetrexed · Drug: Carboplatin

  • Active comparator
    Gemcitabine/Vinorelbine

    Vinorelbine 30 mg/m\^2 was given over approximately 6-10 minutes on Day 1 and Day 8. Gemcitabine 1200 mg/m\^2 was given over approximately 30 minutes on Day 1 and Day 8 beginning after the end of the Vinorelbine infusion. The cycle of treatment was 21 days.

    Drug: Gemcitabine · Drug: Vinorelbine

Interventions

  • 600 mg/m\^2, administered intravenously (IV) every 21 days until disease progression or unacceptable toxicity.

    Also known as: LY231514, Alimta

  • AUC 5 mg\*min/mL, administered IV every 21 days until disease progression or unacceptable toxicity.

  • 1200 mg/m\^2 gemcitabine, administered IV on day 1 and day 8 every 21 days until disease progression or unacceptable toxicity.

    Also known as: LY188011, Gemzar

  • 30 mg/m\^2 vinorelbine administered IV on day 1 and day 8 every 21 days until disease progression or unacceptable toxicity.

06

What researchers measure

Primary outcomes

  1. Tumor Response Rate

    Participants with best overall response determined from complete response (CR) or partial response (PR) according to Response Criteria in Solid Tumors (RECIST) criteria. For CR or PR, best response must be confirmed. A second assessment performed at 28 days. Two determinations of CR before progression required for rate to=CR. Evaluations include: CR=Disappearance of lesions. PR=≥30% size decrease of lesions. Progressive Disease (PD)=≥20% size increase of lesions. Stable Disease (SD)=Not enough shrinkage for PR nor enough increase for PD. Overall Response Rate=PR+CR/Qualified Participants\*100.

    Time frame: Baseline up to 30 days of follow-up after 21 cycles of treatment

Secondary outcomes

  1. Duration of Response (DOR)

    DOR-RECIST criteria of (Complete Response \[CR =Disappearance of lesions\] or Partial Response \[PR=≥30% size decrease of lesions\]) is defined as time from the date when measurement criteria are met for CR or PR until the date of first observation of progressive disease (PD) or death from study disease. For participants who die from causes other than study disease and without PD, DOR will be censored at the date of death. For participants who have not died as of the data cut-off date who are without PD, DOR was censored at last contact date.

    Time frame: Time of response to progressive disease (up to 19 months)

  2. Time to Progressive Disease (PD)

    Time to PD is defined as the time from the date of study enrollment to the first documented date of PD or death from study disease. For participants who die from causes other than study disease and without PD, time to PD was censored at the date of death. For participants not known to have died as of the data cut-off date and do not have PD, time to PD was censored at the last contact date. For participants who received subsequent chemotherapy (after discontinuation from the study chemotherapy) prior to disease progression, time to PD was censored at the date of subsequent chemotherapy.

    Time frame: Baseline to measured PD (up to 25.1 months)

  3. Time To Treatment Failure (TTTF)

    TTTF is defined as the time from date of study enrollment to the first documented date of death, PD, or study treatment discontinuation due to adverse event (AE). For participants not known to have discontinued as of the data cut-off date, TTTF is censored at the last contact date. For participants who discontinued for reasons other than death, PD, or AE, TTTF is censored at the date of discontinuation.

    Time frame: Baseline to end of treatment (up to 21.9 months)

  4. Time to Response

    Time to response (Complete Response(CR) or Partial Response (PR) is defined as the time from the date of study enrollment to the first date when the measurement criteria are met for complete response or partial response (whichever status is recorded first). CR=Disappearance of target lesions lesions. PR=≥30% size decrease of lesions.

    Time frame: Baseline to response (up to 7.8 months)

  5. Number of Participants With Adverse Events (AE)

    A listing of adverse events is presented in the Reported Adverse Event Module.

    Time frame: every cycle up to twenty-one 21-day cycles (plus 30 days of follow-up)

07

Results

Posted May 20, 2011

Participant flow

Participant flow — Overall Study
MilestonePemetrexed/CarboplatinGemcitabine/Vinorelbine
Started6966
Received at least 1 dose of study drug6566
Completed00
Not completed6966
Withdrew: Adverse event107
Withdrew: Death due to study disease10
Withdrew: Entry criteria not met12
Withdrew: Subject decision68
Withdrew: Physician decision1712
Withdrew: Progressive disease3437

Outcome measures

PrimaryTumor Response Rate

Participants with best overall response determined from complete response (CR) or partial response (PR) according to Response Criteria in Solid Tumors (RECIST) criteria. For CR or PR, best response must be confirmed. A second assessment performed at 28 days. Two determinations of CR before progression required for rate to=CR. Evaluations include: CR=Disappearance of lesions. PR=≥30% size decrease of lesions. Progressive Disease (PD)=≥20% size increase of lesions. Stable Disease (SD)=Not enough shrinkage for PR nor enough increase for PD. Overall Response Rate=PR+CR/Qualified Participants\*100.

Time frame:
Baseline up to 30 days of follow-up after 21 cycles of treatment
Reported as:
Number · percentage of participants
Tumor Response Rate
percentage of participantsPemetrexed/CarboplatinGemcitabine/Vinorelbine
Overall Response26.6 (16.3 to 39.1)29.5 (18.5 to 42.6)
Complete Response0.0 (0.0 to 5.6)3.3 (0.4 to 11.3)
Partial Response26.6 (16.3 to 39.1)26.2 (15.8 to 39.1)
Stable Disease35.9 (24.3 to 48.9)34.4 (22.7 to 47.7)
Progressive Disease26.6 (16.3 to 39.1)27.9 (17.1 to 40.8)
Unknown10.9 (4.5 to 21.2)8.2 (2.7 to 18.1)
SecondaryDuration of Response (DOR)

DOR-RECIST criteria of (Complete Response \[CR =Disappearance of lesions\] or Partial Response \[PR=≥30% size decrease of lesions\]) is defined as time from the date when measurement criteria are met for CR or PR until the date of first observation of progressive disease (PD) or death from study disease. For participants who die from causes other than study disease and without PD, DOR will be censored at the date of death. For participants who have not died as of the data cut-off date who are without PD, DOR was censored at last contact date.

Time frame:
Time of response to progressive disease (up to 19 months)
Reported as:
Median · Months
Duration of Response (DOR)
MonthsPemetrexed/CarboplatinGemcitabine/Vinorelbine
Duration of Response (DOR)7.7 (4.2 to 12.2)7.5 (4.9 to 8.3)
SecondaryTime to Progressive Disease (PD)

Time to PD is defined as the time from the date of study enrollment to the first documented date of PD or death from study disease. For participants who die from causes other than study disease and without PD, time to PD was censored at the date of death. For participants not known to have died as of the data cut-off date and do not have PD, time to PD was censored at the last contact date. For participants who received subsequent chemotherapy (after discontinuation from the study chemotherapy) prior to disease progression, time to PD was censored at the date of subsequent chemotherapy.

Time frame:
Baseline to measured PD (up to 25.1 months)
Reported as:
Median · Months
Time to Progressive Disease (PD)
MonthsPemetrexed/CarboplatinGemcitabine/Vinorelbine
Time to Progressive Disease (PD)5.1 (4.1 to 8.0)5.6 (4.2 to 7.5)
SecondaryTime To Treatment Failure (TTTF)

TTTF is defined as the time from date of study enrollment to the first documented date of death, PD, or study treatment discontinuation due to adverse event (AE). For participants not known to have discontinued as of the data cut-off date, TTTF is censored at the last contact date. For participants who discontinued for reasons other than death, PD, or AE, TTTF is censored at the date of discontinuation.

Time frame:
Baseline to end of treatment (up to 21.9 months)
Reported as:
Median · Months
Time To Treatment Failure (TTTF)
MonthsPemetrexed/CarboplatinGemcitabine/Vinorelbine
Time To Treatment Failure (TTTF)4.8 (3.3 to 7.0)5.1 (3.5 to 6.3)
SecondaryTime to Response

Time to response (Complete Response(CR) or Partial Response (PR) is defined as the time from the date of study enrollment to the first date when the measurement criteria are met for complete response or partial response (whichever status is recorded first). CR=Disappearance of target lesions lesions. PR=≥30% size decrease of lesions.

Time frame:
Baseline to response (up to 7.8 months)
Reported as:
Median · Months
Time to Response
MonthsPemetrexed/CarboplatinGemcitabine/Vinorelbine
Time to Response1.8 (1.6 to 3.3)1.8 (1.6 to 3.1)
SecondaryNumber of Participants With Adverse Events (AE)

A listing of adverse events is presented in the Reported Adverse Event Module.

Time frame:
every cycle up to twenty-one 21-day cycles (plus 30 days of follow-up)
Reported as:
Number · participants
Number of Participants With Adverse Events (AE)
participantsPemetrexed/CarboplatinGemcitabine/Vinorelbine
Adverse Events6466
Serious Adverse Events1822

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pemetrexed/Carboplatin—18/65 (27.7%)64/65 (98.5%)
Gemcitabine/Vinorelbine—22/66 (33.3%)66/66 (100%)
Most frequent serious events
Showing 10 of 44
Most frequent serious events
EventPemetrexed/CarboplatinGemcitabine/Vinorelbine
ThrombocytopeniaBlood and lymphatic system disorders6/650/66
AnaemiaBlood and lymphatic system disorders5/651/66
NeutropeniaBlood and lymphatic system disorders4/652/66
VomitingGastrointestinal disorders3/651/66
PyrexiaGeneral disorders2/653/66
PneumoniaInfections and infestations2/650/66
HypokalaemiaMetabolism and nutrition disorders2/650/66
Febrile neutropeniaBlood and lymphatic system disorders1/652/66
NauseaGastrointestinal disorders1/650/66
Performance status decreasedGeneral disorders1/650/66
Most frequent other events
Showing 10 of 43
Most frequent other events
EventPemetrexed/CarboplatinGemcitabine/Vinorelbine
NeutropeniaBlood and lymphatic system disorders37/6551/66
LeukopeniaBlood and lymphatic system disorders28/6535/66
AnaemiaBlood and lymphatic system disorders32/6528/66
NauseaGastrointestinal disorders31/6523/66
ConstipationGastrointestinal disorders18/6526/66
FatigueGeneral disorders23/6526/66
PyrexiaGeneral disorders5/6521/66
Alanine aminotransferase increasedInvestigations11/6521/66
ThrombocytopeniaBlood and lymphatic system disorders17/6511/66
Aspartate aminotransferase increasedInvestigations9/6517/66

Baseline characteristics

Age Continuous
Age Continuous(years)Pemetrexed/CarboplatinGemcitabine/VinorelbineTotal
Mean51.9 ± 11.3852.3 ± 10.4052.1 ± 10.87
Sex: Female, Male
Sex: Female, Male(Participants)Pemetrexed/CarboplatinGemcitabine/VinorelbineTotal
Female6966135
Male000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Pemetrexed/CarboplatinGemcitabine/VinorelbineTotal
Caucasian6761128
African134
Hispanic011
East Asian101
West Asian011
Region of Enrollment
Region of Enrollment(participants)Pemetrexed/CarboplatinGemcitabine/VinorelbineTotal
Spain181836
Switzerland549
Israel9918
Germany91221
Italy161430
Turkey538
South Africa7613
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(participants)Pemetrexed/CarboplatinGemcitabine/VinorelbineTotal
ECOG 0393978
ECOG 1282755
ECOG 2202
Hormonal Receptor Status
Hormonal Receptor Status(participants)Pemetrexed/CarboplatinGemcitabine/VinorelbineTotal
Estrogen and Progesterone Negative192140
Estrogen and/or Progesterone Positive494493
Unknown112
Human Epidermal Growth Factor Receptor 2 (HER-2/Neu)
Human Epidermal Growth Factor Receptor 2 (HER-2/Neu)(participants)Pemetrexed/CarboplatinGemcitabine/VinorelbineTotal
Positive121325
Negative5349102
Not Performed011
Unknown437
Tumor Differentiation Grade
Tumor Differentiation Grade(participants)Pemetrexed/CarboplatinGemcitabine/VinorelbineTotal
Grade I639
Grade II252752
Grade III323062
Unknown6612

1 further baseline measures are reported on the registry.

08

Study locations

22 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Guetersloh, 33332, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hamburg, 22081, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Stuttgart, 70190, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bergamo, 24128, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bologna, 40139, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Livorno, 57128, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Meldola, 47014, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Rome, 00168, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Giovanni Rotondo, 71013, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Durban, 4067, South Africa
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Morningside, 2199, South Africa
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Pretoria, 0001, South Africa
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Barcelona, 08036, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Girona, 17007, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    La Coruña, 15006, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lleida, 25198, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Madrid, 28040, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Valencia, 46010, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Zaragoza, 50009, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Besevler/Ankara, 06500, Turkey
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bornova, 35100, Turkey
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kayseri, 38039, Turkey
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2006, a primary completion of Apr 2010 and a completion of Aug 2010. It does not say whether these dates are actual or estimated.

Results were first posted in May 2011, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2006
First posted
May 12, 2006
Start
Jun 2006
Primary completionActual
Apr 2010
CompletionActual
Aug 2010
Results first posted
May 20, 2011
Last update
May 20, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00325234
First posted
May 12, 2006
Start date
Jun 2006
Primary completion
Apr 2010
Completion
Aug 2010
Results posted
May 20, 2011
Last update
May 20, 2011

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon- Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pemetrexed · Carboplatin

Start the discussion